Based on the Cara Therapeutic stock forecast from 0 analysts, the average analyst target price for Cara Therapeutic is not available over the next 12 months. Cara Therapeutic’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cara Therapeutic is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Cara Therapeutic’s stock price was USD 5.22. Cara Therapeutic’s stock price has changed by +1,280.95% over the past week, +1,805.11% over the past month and -34.57% over the last year.
No recent analyst target price found for Cara Therapeutic
No recent average analyst rating found for Cara Therapeutic
Company Overview Cara Therapeutic
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Read Less
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-seve...Read More
Frequently Asked Questions About Cara Therapeutic (CARA) Stock
Stock Target Advisor's fundamental analysis for Cara Therapeutic's stock is Bearish.
Unfortunately we do not have enough data on CARA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CARA's stock to indicate what its average analyst target is.
CARA stock's Price/Earning ratio is 23.13.
Our analysis grades CARA stock's Price / Earning ratio at F. This means that CARA stock's Price/Earning ratio is above 73% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CARA may be a overvalued for its sector.
The last closing price of CARA's stock was USD 5.22.
The most recent market capitalization for CARA is USD 0.02B.
Unfortunately we do not have enough analyst data on CARA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cara Therapeutic's stock.
As per our most recent records Cara Therapeutic has 55 Employees.
Cara Therapeutic's registered address is 400 Atlantic Street, Stamford, CT, United States, 06901.
You can get more information about it from Cara Therapeutic's website at https://www.caratherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Cara Therapeutic (CARA) Stock
Stock Target Advisor's fundamental analysis for Cara Therapeutic's stock is Bearish.
Unfortunately we do not have enough data on CARA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CARA's stock to indicate what its average analyst target is.
CARA stock's Price/Earning ratio is 23.13.
Our analysis grades CARA stock's Price / Earning ratio at F. This means that CARA stock's Price/Earning ratio is above 73% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CARA may be a overvalued for its sector.
The last closing price of CARA's stock was USD 5.22.
The most recent market capitalization for CARA is USD 0.02B.
Unfortunately we do not have enough analyst data on CARA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cara Therapeutic's stock.
As per our most recent records Cara Therapeutic has 55 Employees.
Cara Therapeutic's registered address is 400 Atlantic Street, Stamford, CT, United States, 06901.
You can get more information about it from Cara Therapeutic's website at https://www.caratherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CARA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
